BCR-ABL-induced deregulation of the IL-33/ST2 pathway in Cd34(+) progenitors from chronic myeloid leukemia patients

Cancer Research

Volumn 74, Issue 10, 2014, Pages 2669-2676

  Levescot, Anaïs ^a,b   Flamant, Stéphane ^a   Basbous, Sara ^a,c   Jacomet, Florence ^a,c,d,e   Féraud, Olivier ^a   Bourgeois, Elvire Anne ^a   Bonnet, Marie Laure ^a,e   Giraud, Christine ^a,e,f,g   Roy, Lydia ^a,c,e,g   Barra, Anne ^a,c,d,e   Chomel, Jean Claude ^a,e,h   Turhan, Ali ^a,c,e,i   Guilhot, François ^a,c,e,g   Girard, Jean Philippe ^j,k   Gombert, Jean Marc ^a,c,d,e   Herbelin, André ^a,c,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITÉ DE POITIERS   (France)

^d Service d'Immunologie et Inflammation   (France)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f ETABLISSEMENT FRANÇAIS DU SANG   (France)

^g Service d'Oncologie Hématologique et Thérapie Cellulaire   (France)

^h Service de Cancerologie Biologique   (France)

ⁱ Service d'Hematologie et d'Oncologie Biologique   (France)

^j CNRS   (France)

^k UNIVERSITÉ DE TOULOUSE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; INTERLEUKIN 33; INTERLEUKIN RECEPTOR; ST2 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER PATIENT; CD34+ STEM CELL; CELL GROWTH; CELL PROLIFERATION; CELL SURFACE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE OVEREXPRESSION; GROWTH DISORDER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VOLUME; UPREGULATION; XENOGRAFT;

ANIMALS; ANTIGENS, CD34; BENZAMIDES; CYTOKINES; DRUG INTERACTIONS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INTERLEUKINS; JANUS KINASE 2; LEUKEMIA, MYELOID, CHRONIC-PHASE; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; PIPERAZINES; PYRIMIDINES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84901277246     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2797     Document Type: Article

References (20)

1. Goldman JM, Melo JV. Chronic myeloid leukemia advances in biology and new approaches to treatment. N Engl J Med 2003; 349:1451-64.
2. Druker B, Guilhot F, O'brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med 2006;355:2408-7.
3. Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL progenitors via JAK-2/STAT-5 pathway activation. Blood 2007; 109:2147-55.
4. Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, et al. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.Leukemia 2010;24:771-8.
5. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011;121: 396-409.
6. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
7. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan Tk, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-Associated cytokines. Immunity 2005;23:479-90.
8. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatinassociated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007; 104:282-7.
9. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE 2008;3:e3331.
10. Schulze J, Bickert T, Beil FT, Zaiss MM, Albers J, Wintges K, et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res 2011;26:704-17.
11. Allakhverdi Z,Comeau MR,Smith DE, Toy D, EndamLM, Desrosiers M, et al. CD34 hemopoietic progenitor cells are potent effectors of allergic inflammation. Allergy Clin Immunol 2009;123:472-8.
12. Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol 2012;188:3488-95.
13. Flamant S1, Kortulewski T, Dugray A, Bonnet ML, Guillier M, Guilhot F, et al. Osteopontin is upregulated by BCR-ABL. Biochem Biophys Res Commun 2005;333:1378-84.
14. Jaras M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci U S A 2010;107:16280-5.
15. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293: 876-80.
16. Moore S, Haylock DN, Levesque JP, McDiarmid LA, Samels LM, To LB, et al. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34() cells. Blood 1998;92:2461-70.
17. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935-42.
18. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J ExpMed 2000;191:977-84.
19. Funakoshi-Tago M, Tago K, Sato Y, Tominaga S, Kasahara T. JAK2 is an important signal transducer in IL-33-induced NF-kB activation. Cell Signal 2011;23:363-70.
20. Liew FY, Pitman NI, McInnes IB. Disease-Associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010;10:103-10.